Macroprolactin

Last updated

Macroprolactin is the term used to describe complexed forms of the pituitary hormone prolactin which are found in blood. The most common complex found in blood consists of prolactin and immunoglobulin G (IgG). [1] While the free prolactin hormone is active, prolactin in the macroprolactin complex does not have any biological activity in the body and is considered benign. [2] However, macroprolactin is detected by all Laboratory tests that measure prolactin in blood. [3] This leads to misdiagnosis of hyperprolactinaemia in many people, especially those with other symptoms, such as infertility [4] or menstrual problems. [5]

"Macroprolactin" is most commonly a complex of prolactin and IgG (typically IgG4), displaying a molecular weight of approximately 150 kDa (which is hence 6–7 fold higher that the native molecule). Polymeric aggregate of highly glycosylated prolactin monomers or prolactin-IgA complexes (i.e. non-IgG-type macroprolactin) act similarly and also count as "macroprolactin". [6]

In patients with hyperprolactinemia, the serum pattern of prolactin isoforms usually encompasses 60%–90% monomeric prolactin, 15%–30% big-prolactin (4060 kDa: usually prolactin dimers or big-big degradation products) and 0%–10% big-big prolactin (>100 kDa). [7] The condition of macroprolactinaemia is hence defined as predominance (i.e. >30%–60%) of circulating prolactin isoforms with molecular weight >100 kDa. [8]

There are certain chemicals, such as polyethylene glycol, that can be added to remove macroprolactin from a suspicious sample. The sample can then be re-analysed to see if the prolactin levels are still high. The gold standard test to diagnose macroprolactin is gel-filtration chromatography.

Literature

Related Research Articles

<span class="mw-page-title-main">Androgen insensitivity syndrome</span> Medical condition

Androgen insensitivity syndrome (AIS) is a difference in sex development involving hormonal resistance due to androgen receptor dysfunction.

<span class="mw-page-title-main">Prolactin</span> Protein family and hormone

Prolactin (PRL), also known as lactotropin and mammotropin, is a protein best known for its role in enabling mammals to produce milk. It is influential in over 300 separate processes in various vertebrates, including humans. Prolactin is secreted from the pituitary gland in response to eating, mating, estrogen treatment, ovulation and nursing. It is secreted heavily in pulses in between these events. Prolactin plays an essential role in metabolism, regulation of the immune system and pancreatic development.

<span class="mw-page-title-main">Hyperprolactinaemia</span> Medical condition

Hyperprolactinaemia is the presence of abnormally high levels of prolactin in the blood. Normal levels average to about 13 ng/mL in women, and 5 ng/mL in men, with an upper normal limit of serum prolactin levels being 15-25 ng/mL for both. When the fasting levels of prolactin in blood exceed this upper limit, hyperprolactinemia is indicated.

Anovulation is when the ovaries do not release an oocyte during a menstrual cycle. Therefore, ovulation does not take place. However, a woman who does not ovulate at each menstrual cycle is not necessarily going through menopause. Chronic anovulation is a common cause of infertility.

<span class="mw-page-title-main">Prolactinoma</span> Medical condition

A prolactinoma is a tumor (adenoma) of the pituitary gland that produces the hormone prolactin. It is the most common type of functioning pituitary tumor. Symptoms of prolactinoma are due to abnormally high levels of prolactin in the blood (hyperprolactinemia), or due to pressure of the tumor on surrounding tissues. Based on size, a prolactinoma can be classified as a microprolactinoma or a macroprolactinoma.

<span class="mw-page-title-main">Carney complex</span> Medical condition

Carney complex and its subsets LAMB syndrome and NAME syndrome are autosomal dominant conditions comprising myxomas of the heart and skin, hyperpigmentation of the skin (lentiginosis), and endocrine overactivity. It is distinct from Carney's triad. Approximately 7% of all cardiac myxomas are associated with Carney complex.

The prolactin receptor (PRLR) is a type I cytokine receptor encoded in humans by the PRLR gene on chromosome 5p13-14. It is the receptor for prolactin (PRL). The PRLR can also bind to and be activated by growth hormone (GH) and human placental lactogen (hPL). The PRLR is expressed in the mammary glands, pituitary gland, and other tissues. It plays an important role in lobuloalveolar development of the mammary glands during pregnancy and in lactation.

<span class="mw-page-title-main">Partial androgen insensitivity syndrome</span> Medical condition

Partial androgen insensitivity syndrome (PAIS) is a condition that results in the partial inability of the cell to respond to androgens. It is an X linked recessive condition. The partial unresponsiveness of the cell to the presence of androgenic hormones impairs the masculinization of male genitalia in the developing fetus, as well as the development of male secondary sexual characteristics at puberty, but does not significantly impair female genital or sexual development. As such, the insensitivity to androgens is clinically significant only when it occurs in individuals with a Y chromosome. Clinical features include ambiguous genitalia at birth and primary amenhorrhoea with clitoromegaly with inguinal masses. Müllerian structures are not present in the individual.

<span class="mw-page-title-main">Steroid 11β-hydroxylase</span> Protein found in mammals

Steroid 11β-hydroxylase, also known as steroid 11β-monooxygenase, is a steroid hydroxylase found in the zona glomerulosa and zona fasciculata of the adrenal cortex. Named officially the cytochrome P450 11B1, mitochondrial, it is a protein that in humans is encoded by the CYP11B1 gene. The enzyme is involved in the biosynthesis of adrenal corticosteroids by catalyzing the addition of hydroxyl groups during oxidation reactions.

<span class="mw-page-title-main">HESX1</span> Protein-coding gene in the species Homo sapiens

Homeobox expressed in ES cells 1, also known as homeobox protein ANF, is a homeobox protein that in humans is encoded by the HESX1 gene.

<span class="mw-page-title-main">SRD5A2</span> Protein-coding gene in the species Homo sapiens

The human gene SRD5A2 encodes the 3-oxo-5α-steroid 4-dehydrogenase 2 enzyme, also known as 5α-reductase type 2 (5αR2), one of three isozymes of 5α-reductase.

<span class="mw-page-title-main">IGFBP2</span> Protein-coding gene in the species Homo sapiens

Insulin-like growth factor-binding protein 2 is a protein that in humans is encoded by the IGFBP2 gene.

<span class="mw-page-title-main">PROP1</span> Human gene

Homeobox protein prophet of PIT-1 is a protein that in humans is encoded by the PROP1 gene.

Autoimmune hypophysitis is defined as inflammation of the pituitary gland due to autoimmunity.

<span class="mw-page-title-main">Aromatase deficiency</span> Medical condition

Aromatase deficiency is a rare condition characterized by extremely low levels or complete absence of the enzyme aromatase activity in the body. It is an autosomal recessive disease resulting from various mutations of gene CYP19 (P450arom) which can lead to ambiguous genitalia and delayed puberty in females, continued linear growth into adulthood and osteoporosis in males and virilization in pregnant mothers. As of 2020, fewer than 15 cases have been identified in genetically male individuals and at least 30 cases in genetically female individuals.

<span class="mw-page-title-main">Hypophysitis</span> Medical condition

Hypophysitis refers to an inflammation of the pituitary gland. Hypophysitis is rare and not fully understood.

<span class="mw-page-title-main">Complete androgen insensitivity syndrome</span> Intersex condition that results in a phenotypic female

Complete androgen insensitivity syndrome (CAIS) is an AIS condition that results in the complete inability of the cell to respond to androgens. As such, the insensitivity to androgens is only clinically significant when it occurs in individuals who are exposed to significant amounts of testosterone at some point in their lives. The unresponsiveness of the cell to the presence of androgenic hormones prevents the masculinization of male genitalia in the developing fetus, as well as the development of male secondary sexual characteristics at puberty, but does allow, without significant impairment, female genital and sexual development in those with the condition.

<span class="mw-page-title-main">Mild androgen insensitivity syndrome</span> Medical condition

Mild androgen insensitivity syndrome (MAIS) is a condition that results in a mild impairment of the cell's ability to respond to androgens. The degree of impairment is sufficient to impair spermatogenesis and / or the development of secondary sexual characteristics at puberty in males, but does not affect genital differentiation or development. Female genital and sexual development is not significantly affected by the insensitivity to androgens; as such, MAIS is only diagnosed in males. The clinical phenotype associated with MAIS is a normal male habitus with mild spermatogenic defect and / or reduced secondary terminal hair.

<span class="mw-page-title-main">Leonid Poretsky</span> American endocrinologist

Leonid Poretsky is a Russian-born American endocrinologist. His research interests include mechanisms of insulin action in the ovary, endocrinological aspects of AIDS, and clinical outcomes in diabetes. He has authored over 150 publications and has served on the National Institutes of Health's review committees and on the editorial boards of the Journal of Clinical Endocrinology and Metabolism and other endocrine journals.

The side effects of cyproterone acetate (CPA), a steroidal antiandrogen and progestin, including its frequent and rare side effects, have been studied and characterized. It is generally well-tolerated and has a mild side-effect profile, regardless of dosage, when it used as a progestin or antiandrogen in combination with an estrogen such as ethinylestradiol or estradiol valerate in women. Side effects of CPA include hypogonadism and associated symptoms such as demasculinization, sexual dysfunction, infertility, and osteoporosis; breast changes such as breast tenderness, enlargement, and gynecomastia; emotional changes such as fatigue and depression; and other side effects such as vitamin B12 deficiency, weak glucocorticoid effects, and elevated liver enzymes. Weight gain can occur with CPA when it is used at high doses. Some of the side effects of CPA can be improved or fully prevented if it is combined with an estrogen to prevent estrogen deficiency. Few quantitative data are available on many of the potential side effects of CPA. Pooled tolerability data for CPA is not available in the literature.

References

  1. N Hattori, T Ishihara, K Ikekubo, K Moridera, M Hino, H Kurahachi (1992). "Autoantibody to human prolactin in patients with idiopathic hyperprolactinemia". J Clin Endocrinol Metab. 75 (5): 1226–1229. doi:10.1210/jcem.75.5.1430082. PMID   1430082.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  2. Wallace IR, Satti N, Courtney CH, Leslie H, Bell PM, Hunter SJ, McCance DR, Sheridan B, Atkinson AB. (2010). "Ten-year clinical follow-up of a cohort of 51 patients with macroprolactinaemia establishes it as a benign variant". J Clin Endocrinol Metab. 95 (7): 3268–3271. doi:10.1210/jc.2010-0114. PMID   20427494.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  3. Thomas P. Smith, Abdulwahab M. Suliman, Michael N. Fahie-Wilson, T. Joseph McKenna (2002). "Gross Variability in the Detection of Prolactin in Sera Containing Big Big Prolactin (Macroprolactin) by Commercial Immunoassays". J Clin Endocrinol Metab. 87 (12): 5410–5415. doi:10.1210/jc.2001-011943. PMID   12466327.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  4. K Jayakrishnan (December 2011). "chapter 11". Insights Into Infertility Management. JP Medical Ltd. p. 79. ISBN   9789350255186.
  5. Fahie-Wilson MN, Smith TP. (2013). "Determination of prolactin: the macroprolactin problem". Best Practice & Research Clinical Endocrinology & Metabolism. 27 (5): 725–742. doi:10.1016/j.beem.2013.07.002. PMID   24094642.
  6. Fahie-Wilson, Michael; Smith, Thomas P. (2013-10-01). "Determination of prolactin: The macroprolactin problem". Best Practice & Research Clinical Endocrinology & Metabolism. Endocrine Assays and Pitfalls - Volume I. 27 (5): 725–742. doi:10.1016/j.beem.2013.07.002. ISSN   1521-690X. PMID   24094642.
  7. Lippi, Giuseppe; Plebani, Mario (2016-04-01). "Macroprolactin: searching for a needle in a haystack?". Clinical Chemistry and Laboratory Medicine. 54 (4): 519–522. doi: 10.1515/cclm-2015-1283 . ISSN   1437-4331. PMID   26845727. S2CID   5216254.
  8. Fahie-Wilson, M N; John, R; Ellis, A R (2005-05-01). "Macroprolactin; high molecular mass forms of circulating prolactin". Annals of Clinical Biochemistry: International Journal of Laboratory Medicine. 42 (3): 175–192. doi:10.1258/0004563053857969. ISSN   0004-5632. PMID   15949152. S2CID   24997695.